Plerixafor+G-CSF–mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy
Garyfalia Karponi(Democritus University of Thrace), Evangelia Yannaki(G. Papanikolaou General Hospital), Isabelle Rivière(Memorial Sloan Kettering Cancer Center), Nikoletta Psatha(G. Papanikolaou General Hospital), Νικόλαος Ζώγας(G. Papanikolaou General Hospital), Michel Sadelain(Columbia University Irving Medical Center), Αchilles Anagnostopoulos(G. Papanikolaou General Hospital), Fani Zervou(G. Papanikolaou General Hospital), Carsten W. Lederer(Cyprus Institute of Neurology and Genetics), George Stamatoyannopoulos(University of Washington Medical Center), Marina Kleanthous(Cyprus Institute of Neurology and Genetics), Constantinos Tsatalas(Democritus University of Thrace), Jennifer E. Adair(University of Massachusetts Chan Medical School)
Cited by 49
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Gene therapy comes of age
|Science|2018|1.4k
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
|Cancer Discovery|2021|551
Locus control regions
|Blood|2002|470